I just looked at the NY Times graphic again and at the top is BBIOY
and Marimastat for treating Brain Cancer. Since the same drug and company
is also listed for Pancreatic Cancer, my previous post should be modified
to indicate that LGND is the only company listed twice with two
different compounds (Targretin and Panretin). Since the title of the
article is "Hope Near the End Of the Pipeline" with sub-heading of
"A New Generation of Treatments For Cancer Will Soon Reach Market",
I assume that only phase III trials were listed in the graphic. However,
Panretin is in Phase III trials for Acute Promyelocytic Leukemia
and Targretin is in Phase II/III trials for non-Small Cell Lung Cancer.
LGND has its retinoids in trials for a wide variety of maligancies
(I think the retinoids are in something like 45 different trials!).
Under the more advanced category, Targretin is in Phase IIB trials
for Head & Neck, Kaposi Sarcoma, Ovarian, Prostate, and Renal while
Panretin is in Phase II for Renal, Non-Hodgkin's Lymphoma, Multiple Myeloma,
Prostate, and Ovarian). The list would be markedly longer if phase I
trials were included which would also cover trials started with ALRT1550
as well as several breast cancer trials in combination with Tamoxifen. |
